ArticleJournal of neuroendocrinology2026
Follow-up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi-ENETS Center of Excellence Study.
Article in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to "Methodological and inferential limits before abandoning follow-up in node-negative typical lung carcinoids".Journal of neuroendocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Typical carcinoids (TC) are neuroendocrine malignancies of the lung with low risk of recurrence and a favorable prognosis. It is unclear whether lymph node status and tumor size affect the recurrence risk. Following radical surgery, current guidelines recommend comprehensive follow-up including regular computed tomography (CT) imaging. We aimed to estimate the risk of recurrence in curatively treated patients with TC and to discuss the justification of the current comprehensive follow-up program. We identified all patients diagnosed with TC from 2009 to 2020 at Aarhus University Hospital, Denmark and Copenhagen University Hospital, Rigshospitalet, Denmark. Patients without distant metastases (M0) who underwent radical surgery (R0) were included in the analysis. The risk of recurrence was estimated using the Aalen-Johansen method treating death as a competing risk. Fine-Gray models were used to evaluate the effect of lymph node status and tumor size. Three-hundred and thirty patients were included in the analysis, of whom 40 had lymph node involvement and 290 did not. During a total follow-up time of 2806 years across all patients, with an individual median of 8.1 years (IQR: 5.9-11.2), 10 patients had recurrence: four in the node-negative group and six in the node-positive group. The 10-year cumulative risk of recurrence for all patients was 3.4% (95% confidence interval (CI): 1.7-6.0), for patients without lymph node involvement 1.6% (95% CI: 0.5-3.8), and for patients with lymph node involvement 15.6% (95% CI: 6.3-28.8). Of the four recurrences in the node-negative group, one led to re-resection with curative intent. Patients with TC without lymph node involvement have a very low risk of recurrence. Thus, we recommend tailoring the follow-up program based on lymph node status, with node-negative patients being excluded from regular follow-up programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.